Gujarat Themis raises $58 million for Japanese pharma acquisition

Gujarat Themis Chemical and Pharmaceutical Company has closed a $58 million private credit facility to support its strategic acquisition in Japan, signalling the Indian drugmaker's growing ambitions in the international pharmaceutical sector.

The company, established in 1981, holds a notable place in India's pharmaceutical history as the first domestic manufacturer to commence commercial production of Rifampicin, a critical anti-tuberculosis medication. The anti-TB drug remains central to India's disease management efforts, with the country bearing a substantial global tuberculosis burden.

The private credit financing demonstrates investor confidence in Gujarat Themis's business model and growth trajectory. The Japanese acquisition represents the company's push to expand its international footprint and enhance its product portfolio beyond its core tuberculosis treatment focus.

Gujarati pharmaceutical companies have increasingly pursued overseas acquisitions and partnerships to access new markets and technologies. This transaction aligns with broader trends in India's pharmaceutical sector, where domestic companies are leveraging their manufacturing expertise and cost advantages to acquire assets abroad.

Details regarding the specific Japanese acquisition target and the transaction timeline were not immediately disclosed. The funding arrangement underscores how Indian mid-sized pharmaceutical firms are accessing diverse financing mechanisms to fuel their international expansion strategies.